Blood test may predict which triple-negative breast cancers will return

NCT ID NCT06418126

Ongoing Knowledge-focused Sponsor: Centre Paul Strauss Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study looks at whether measuring certain inflammatory proteins (cytokines) in the blood during radiotherapy can help predict which triple-negative breast cancer patients are likely to have their cancer come back. Researchers will take blood samples from 15 women before and during radiotherapy and track their health for up to 5 years. The goal is to find a simple way to identify high-risk patients who might need extra treatment.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to: If successful, this could lead to a blood test that identifies which TNBC patients are at high risk of recurrence after radiotherapy.
What could go wrong: This is a very small, early-stage study with only 15 participants. It is observational and does not test a new treatment, so results may not lead to a usable test.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for TRIPLE NEGATIVE BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

triple-negative breast carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

TRIPLE NEGATIVE BREAST CANCER

Contacts and locations

Locations

Institut de cancérologie Strasbourg europe

Strasbourg, 67033, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.